Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial

BACKGROUND: Mexico has one of the highest prevalence rates of obesity worldwide. New pharmacological strategies that focus on people with class III obesity are required. Metformin and dapagliflozin are two drugs approved for the treatment of diabetes. Beyond its effects on glucose, metformin has bee...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferreira-Hermosillo, Aldo, Molina-Ayala, Mario Antonio, Molina-Guerrero, Diana, Garrido-Mendoza, Ana Pamela, Ramírez-Rentería, Claudia, Mendoza-Zubieta, Victoria, Espinosa, Etual, Mercado, Moisés
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023779/
https://www.ncbi.nlm.nih.gov/pubmed/32059692
http://dx.doi.org/10.1186/s13063-020-4121-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023779/
https://www.ncbi.nlm.nih.gov/pubmed/32059692
http://dx.doi.org/10.1186/s13063-020-4121-x

Ejemplares similares